— Value Proposition: Long non-coding RNA as biomarker and therapeutic target for treating diagnosed multiple myeloma patients.
Technology Description
Researchers at Washington University in St. Louis have developed a long non-coding RNA as a diagnostic marker and clinical target for multiple my…
—
Value proposition: Novel approach to treat chronic itch through the intrathecal or intranasal delivery of JAK inhibitors.
Technology Description
Researchers at Washington University in St. Louis have developed a new method for treating chronic idiopathic pruritus (CIP) in both patients and m…
— Value proposition: Fluorescent oxonol dyes that can be used to enhance bioimaging for the treatment of cancer.
Technology Description
Researchers at Washington University in St. Louis have developed a new class of fluorescent oxonol dyes that exhibit absorption and emission in the near infrared…
— T-017429 Engineered Oncolytic Zika Virus Therapy for Glioblastoma
Technology Description
Researchers in the laboratories of Michael Diamond and Milan Chheda at Washington University have developed prospective treatments for glioblastoma (GBM) through the application of an engineered Zika virus (ZI…
— Technology Description
Researchers in Angela Hirbe’s lab at Washington University have developed a method of treating malignant peripheral nerve sheath tumors (MPNSTs) with a combination of inhibitors. The most effective therapy is to combine an inhibitor of TYK2 with a MEK inhibitor.
MPNST…
| Name | # Summaries | Author |
|---|---|---|
| 15 | ||
| 13 | ||
| 15 | ||
| 26 | ||
| 14 | ||
| 14 |
Creating...
